SGEN — Seagen Share News
0.000.00%
Last trade - 00:00HealthcareBalancedLarge Cap
- $43.15bn
- $41.92bn
- $1.96bn
Seagen Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Groundbreaking EV-302 Trial Significantly Extends Overall Survival And Progression-Free Survival In Patients Treated With Padcev And Keytruda In First-Line Advanced Bladder Cancer
Brief: Tivdak Significantly Prolonged Overall Survival In Patients With Recurrent Or Metastatic Cervical Cancer Compared With Chemotherapy In Global Phase 3 Innovatv 301 Trial
Merck’s cancer rush may spawn lower returns
Deals of the day-Mergers and acquisitions
Pfizer wins unconditional EU antitrust okay for $43 bln Seagen buy
Texas District Court Issues Amended Final Judgment In Patent Dispute Between Daiichi Sankyo And Seagen
U.S. STOCKS ON THE MOVE-Starbucks, Williams-Sonoma, FedEx
U.S. STOCKS ON THE MOVE-Soligenix, Enovis, Lifeway Foods
Merck's Keytruda-ADC drug combo 'support superiority' to chemotherapy - brokerage
Seagen jumps as combination therapy succeeds in bladder cancer trial
U.S. STOCKS ON THE MOVE-Ford, Energy firms, Natgas firms
U.S. STOCKS ON THE MOVE-China ADRs, Wayfair, Seagen
Seagen jumps as combination therapy succeeds in bladder cancer trial
Brief: Seagen Says EV-302 Study Met Its Dual Primary Endpoints
Brief: Astellas Pharma Inc - Padcev And Keytruda Significantly Improve Overall Survival And Progression-Free Survival In Patients With Previously Untreated Advanced Bladder Cancer
Deals of the day-Mergers and acquisitions
EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal
Brief: Nurix Therapeutics Inc - Entered Into A Multi-Year, Multi-Target Strategic Collaboration Agreement With Seagen Inc